Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Return on Sales (2022 - 2025)

Historic Return on Sales for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to 1.54%.

  • InMed Pharmaceuticals' Return on Sales fell 2100.0% to 1.54% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.71%, marking a year-over-year decrease of 3400.0%. This contributed to the annual value of 1.65% for FY2025, which is 200.0% up from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Return on Sales of 1.54% as of Q3 2025, which was down 2100.0% from 1.37% recorded in Q2 2025.
  • In the past 5 years, InMed Pharmaceuticals' Return on Sales registered a high of 0.15% during Q2 2023, and its lowest value of 16.16% during Q4 2021.
  • Moreover, its 5-year median value for Return on Sales was 1.81% (2023), whereas its average is 4.71%.
  • As far as peak fluctuations go, InMed Pharmaceuticals' Return on Sales soared by 151400bps in 2023, and later crashed by -13600bps in 2024.
  • Quarter analysis of 5 years shows InMed Pharmaceuticals' Return on Sales stood at 16.16% in 2021, then soared by 72bps to 4.47% in 2022, then skyrocketed by 73bps to 1.19% in 2023, then crashed by -94bps to 2.32% in 2024, then skyrocketed by 33bps to 1.54% in 2025.
  • Its last three reported values are 1.54% in Q3 2025, 1.37% for Q2 2025, and 1.68% during Q1 2025.